Hasil Pencarian (11793)
Halaman 57 / 236Deskripsi belum tersedia.
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the re…
Bleomycin A2 is under investigation in clinical trial NCT00026208 (Combination Chemotherapy Plus Low-dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma).
Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Ca…
Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients).
Bleximenib is under investigation in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and NCT05453903 (A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies)
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an ant…
Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
Deskripsi belum tersedia.
BLXA4 has been used in trials studying the treatment of Gingival Inflammation.
Deskripsi belum tersedia.
BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA. It is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD).
Deskripsi belum tersedia.
BMS-184476 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3)…
BMS-394136 has been used in trials studying the diagnostic of Heart Diseases.
BMS-488043 has been investigated as an anti-HIV agent.
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
BMS-582949 has been investigated for the treatment of Psoriasis.
BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
BMS-690514 has been investigated for the treatment of Breast Cancer.
BMS-741672 is under investigation in clinical trial NCT00699790 (Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance).
BMS-754807 is under investigation in clinical trial NCT00908024 (Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors).
BMS-770767 is under investigation in clinical trial NCT01058083 (Safety Study of BMS-770767 in Subjects With Hypercholesterolemia).
BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
BMS-830216 is under investigation in clinical trial NCT00909766 (Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects).
Deskripsi belum tersedia.
BMS-863233 has been investigated for the treatment of Refractory Hematologic Cancer.
BMS-903452 has been used in trials studying the treatment of Diabetes.
BMS-908662 has been used in trials studying the treatment of Melanoma and Colorectal Cancer.
BMS-955176 is under investigation in clinical trial NCT02415595 (Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults).
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
BMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers).
INX-08189 has been used in trials studying the treatment of Hepatitis C, HCV (Genotype 1), and Hepatitis C Virus.
BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).
BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer.
BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).
BMS-986142 is under investigation in clinical trial NCT02880670 (Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects).
BMS-986158 is under investigation in clinical trial NCT02419417 (Study of BMS-986158 in Subjects With Select Advanced Cancers).
BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).